EP1109582A4 - Methods to enhance and confine expression of genes - Google Patents

Methods to enhance and confine expression of genes

Info

Publication number
EP1109582A4
EP1109582A4 EP99943819A EP99943819A EP1109582A4 EP 1109582 A4 EP1109582 A4 EP 1109582A4 EP 99943819 A EP99943819 A EP 99943819A EP 99943819 A EP99943819 A EP 99943819A EP 1109582 A4 EP1109582 A4 EP 1109582A4
Authority
EP
European Patent Office
Prior art keywords
genes
enhance
methods
confine
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99943819A
Other languages
German (de)
French (fr)
Other versions
EP1109582A1 (en
Inventor
Yuen Kai Fung
Charles Gomer
Ang Anne T
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of EP1109582A1 publication Critical patent/EP1109582A1/en
Publication of EP1109582A4 publication Critical patent/EP1109582A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
EP99943819A 1998-08-18 1999-08-18 Methods to enhance and confine expression of genes Withdrawn EP1109582A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9694798P 1998-08-18 1998-08-18
US96947P 1998-08-18
PCT/US1999/019095 WO2000010612A1 (en) 1998-08-18 1999-08-18 Methods to enhance and confine expression of genes

Publications (2)

Publication Number Publication Date
EP1109582A1 EP1109582A1 (en) 2001-06-27
EP1109582A4 true EP1109582A4 (en) 2004-11-03

Family

ID=22259886

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99943819A Withdrawn EP1109582A4 (en) 1998-08-18 1999-08-18 Methods to enhance and confine expression of genes

Country Status (11)

Country Link
EP (1) EP1109582A4 (en)
JP (1) JP2002523032A (en)
KR (1) KR20020013463A (en)
CN (1) CN1321093A (en)
AU (1) AU763183B2 (en)
CA (1) CA2340929A1 (en)
IL (1) IL141473A0 (en)
NZ (1) NZ509966A (en)
RU (1) RU2226108C2 (en)
WO (1) WO2000010612A1 (en)
ZA (1) ZA200101207B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003253379A1 (en) * 2002-08-09 2004-03-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression
KR20030019282A (en) * 2002-11-27 2003-03-06 김상태 Development of alzhemier-inducible cell line by Tet-On with recombinant pCT105 vector in βAPP
JP2008532553A (en) * 2005-03-16 2008-08-21 メタボリックス， インコーポレイテッド Chemically inducible expression of biosynthetic pathways
MX2012005340A (en) * 2009-11-05 2012-12-05 Proyecto Biomedicina Cima Sl Regulated expression systems.
CN101892256B (en) * 2010-01-27 2012-05-09 中国农业科学院北京畜牧兽医研究所 Method for breeding transgenic animal with improved pig growth hormone expression level
CN103889440A (en) 2011-08-08 2014-06-25 Cl昂科莱吉有限公司 Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
CN102786599B (en) * 2012-08-01 2014-01-15 中国农业科学院作物科学研究所 Application of rice transcription factor Os05g39950 gene
CA2935232A1 (en) 2013-12-29 2015-07-02 Curelab Oncology, Inc. Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
CN105925609B (en) * 2016-07-14 2019-01-08 中国医学科学院输血研究所 The recombinant vector and construction method that Tet-on induction with marker gene is overexpressed
CN110016464A (en) * 2018-01-08 2019-07-16 张晋宇 For screening the system and method for antitumorigenic substance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027021A1 (en) * 1995-03-01 1996-09-06 Cornell Research Foundation, Inc. Interdependent adenoviral vectors and methods of using same
WO1998006864A2 (en) * 1996-08-15 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027021A1 (en) * 1995-03-01 1996-09-06 Cornell Research Foundation, Inc. Interdependent adenoviral vectors and methods of using same
WO1998006864A2 (en) * 1996-08-15 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HALLAHAN D E ET AL: "SPATIAL AND TEMPORAL CONTROL OF GENE THERAPY USING IONIZING RADIATION", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 1, no. 8, August 1995 (1995-08-01), pages 786 - 791, XP000857200, ISSN: 1078-8956 *
MAUCERI H J ET AL: "TUMOR NECROSIS FACTOR ALPHA(TNT-ALPHA) GENE THERAPY TARGETED BY IONIZING RADIATION SELECTIVELY DAMAGES TUMOR VASCULATURE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, 1996, pages 4311 - 4314, XP002936211, ISSN: 0008-5472 *
See also references of WO0010612A1 *
WEICHSELBAUM R R ET AL: "GENE THERAPY TARGETED BY RADIATION PREFERENTIALLY RADIOSENSITIZES TUMOR CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, 15 August 1994 (1994-08-15), pages 4266 - 4269, XP002932030, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
ZA200101207B (en) 2007-01-31
KR20020013463A (en) 2002-02-20
CN1321093A (en) 2001-11-07
WO2000010612A1 (en) 2000-03-02
NZ509966A (en) 2003-07-25
JP2002523032A (en) 2002-07-30
CA2340929A1 (en) 2000-03-02
AU5684599A (en) 2000-03-14
AU763183B2 (en) 2003-07-17
IL141473A0 (en) 2002-03-10
EP1109582A1 (en) 2001-06-27
RU2226108C2 (en) 2004-03-27

Similar Documents

Publication Publication Date Title
HUP0102598A3 (en) Expression of trehalose biosynthetic genes in plants
PL340760A1 (en) Genes of desaturase and their application
HUP0103329A3 (en) Expression and export of angiostatin and endostatin as immunofusis
IL131486A0 (en) Gene sequencer and methods
EP1261391A4 (en) Regulation of genes via application of specific and selective electrical and electromagnetic signals
AP2000001762A0 (en) Method of delivering genes to antigen presenting cells of the skin
AU1194802A (en) DNA expression vectors and methods of use
AU2001292842A1 (en) Compositions and methods relating to prostate specific genes and proteins
EP1183030A4 (en) Methods of making and using n-desmethylzopiclone
EP1119365A4 (en) Composition and method of using tumor cells
GB9706381D0 (en) Improvements relating to the specificity of gene expression
EP1109582A4 (en) Methods to enhance and confine expression of genes
HUP0201866A2 (en) Maize npr1 polynucleotides and methods of use
EP0748376A4 (en) Rna editing enzyme and methods of use thereof
EP1088054A4 (en) Genes of carotenoid biosynthesis and metabolism and methods of use thereof
EP1070141A4 (en) Immediate early genes and methods of use therefor
EP1317271A4 (en) Therapeutic and cosmetic uses of heparanases
AU9221098A (en) Selective expression of genes in plants
PL352326A1 (en) Noval vegetable genes and use of same
HUP0204093A3 (en) Sorghum dwarfing genes and methods of use
GB9721075D0 (en) Materials and methods relating to the stimulation of cells
AU1576501A (en) Methods to enhance and confine gene expression in cancer therapy
PL330405A1 (en) Ozone-induced expression of genes in plants
AU6387699A (en) Rac-like genes and methods of use
EP1210111A4 (en) Gamma-herpesvirus dna and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040921

17Q First examination report despatched

Effective date: 20050421

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051103